Sign in

    Benjamin Burnett

    Managing Director and Equity Research Analyst at Stifel, Nicolaus & Company, Incorporated

    Benjamin Burnett, Ph.D., is a Managing Director and Equity Research Analyst at Stifel, Nicolaus & Company, Incorporated, specializing in the biotechnology sector. He provides coverage of companies including Iovance, Cabaletta Bio, Arcellx, Revolution Medicines, Fate Therapeutics, CRISPR Therapeutics, and Disc Medicine, with a recent performance record showing a TipRanks success rate of 37.3% and an average return of -7.0% over the past year. Burnett joined Stifel in 2018 after prior roles as Principal at Jefferies LLC and Associate at Leerink Partners, and holds a doctorate from Weill Cornell Medical College as well as degrees from Florida Institute of Technology and Embry-Riddle Aeronautical University. He is recognized for in-depth technical analysis and industry insight, and maintains active professional securities credentials including FINRA registration.

    Benjamin Burnett's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership

    Benjamin Burnett's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership • Q4 2024

    Question

    Benjamin Burnett asked for physician feedback on the evolving competitive landscape in advanced melanoma, particularly regarding a potential new entrant expected later in the year.

    Answer

    Interim CEO and President Frederick Vogt stated that Iovance views the potential new entrant as very similar to the currently marketed T-VEC, with clinical data from a much earlier-line patient population that is not comparable to Amtagvi's. He concluded that they do not anticipate a significant impact on the Amtagvi launch.

    Ask Fintool Equity Research AI

    Benjamin Burnett's questions to IOVANCE BIOTHERAPEUTICS (IOVA) leadership • Q3 2024

    Question

    Benjamin Burnett of Stifel asked about Iovance's path to achieving its 70% gross margin goal and the specific operational levers that will be utilized to reach that target.

    Answer

    Interim CEO Frederick Vogt and CFO Jean-Marc Bellemin responded. They explained that increased capacity utilization at the company's ICTC facility is a primary driver. They also cited ongoing operational excellence initiatives, process improvements, automation, and better raw material cost management as key levers to improve margins over time.

    Ask Fintool Equity Research AI

    Benjamin Burnett's questions to Revolution Medicines (RVMD) leadership

    Benjamin Burnett's questions to Revolution Medicines (RVMD) leadership • Q4 2024

    Question

    Benjamin Burnett of Stifel requested more details on the planned Q2 data update for zoldonrasib and asked about overlapping toxicities and the perceived debate around combining daraxonrasib with chemotherapy.

    Answer

    CEO Dr. Mark Goldsmith declined to provide more color on the upcoming zoldonrasib data. He clarified there is no 'debate' on combinability, but rather a fundamental challenge that standard-of-care chemotherapy alone is often poorly tolerated by PDAC patients. The focus is on managing the chemo backbone's toxicity to ensure continuous, effective dosing of daraxonrasib.

    Ask Fintool Equity Research AI

    Benjamin Burnett's questions to PRECIGEN (PGEN) leadership

    Benjamin Burnett's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    On behalf of Benjamin Burnett, Carolina Ibanez-Ventoso asked about the key factors for the PRGN-2012 rolling BLA submission and the likelihood of an AdCom meeting, given a competitor's recent filing delay.

    Answer

    President and CEO Dr. Helen Sabzevari confirmed that Precigen remains on track for a BLA submission by the end of 2024. She emphasized the drug's differentiation, including its subcutaneous delivery and strong safety profile. Regarding a potential AdCom meeting, Dr. Sabzevari noted that while it is at the FDA's discretion, the remarkable consistency in complete response rates between the Phase I (50%) and Phase II (52%) trials suggests the data is robust and may not require such a review.

    Ask Fintool Equity Research AI

    Benjamin Burnett's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    Carolina Ibanez-Ventoso, on behalf of Benjamin Burnett, asked about the key factors for initiating the rolling BLA submission for PRGN-2012 and the potential for an AdCom meeting with the FDA.

    Answer

    President and CEO Dr. Helen Sabzevari confirmed that the company is on track for a BLA submission by the end of 2024. She emphasized the drug's differentiators, such as subcutaneous delivery and strong efficacy. Regarding a potential AdCom, Dr. Sabzevari noted that while it is at the FDA's discretion, the remarkable consistency between the Phase I (50% complete response) and Phase II (52% complete response) pivotal trials may obviate the need for one.

    Ask Fintool Equity Research AI

    Benjamin Burnett's questions to PRECIGEN (PGEN) leadership • Q2 2024

    Question

    On behalf of Ben Burnett, Carolina Ibanez-Ventoso asked about the key factors for commencing the PRGN-2012 rolling BLA submission and the potential for an AdCom meeting with the FDA.

    Answer

    President and CEO Dr. Helen Sabzevari confirmed that the company is on track for a year-end 2024 BLA submission. She stated that while an AdCom is at the FDA's discretion, she believes the strong consistency between the Phase I (50% complete response) and Phase II (52% complete response) pivotal trial data may obviate the need for one.

    Ask Fintool Equity Research AI